Franklin Resources Inc Fate Therapeutics Inc Transaction History

Franklin Resources Inc

  • $334 Billion
  • Q3 2024

A detailed history of Franklin Resources Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Franklin Resources Inc holds 150,821 shares of FATE stock, worth $250,362. This represents 0.0% of its overall portfolio holdings.

Number of Shares
150,821
Previous 150,821 -0.0%
Holding current value
$250,362
Previous $527,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$3.12 - $5.57 $246,611 - $440,263
-79,042 Reduced 34.39%
150,821 $527,000
Q2 2024

Aug 14, 2024
SELL
$3.26 - $7.08 $117,835 - $255,913
-36,146 Reduced 13.59%
229,863 $753,000
Q1 2024

May 13, 2024
BUY
$3.54 - $8.35 $883,222 - $2.08 Million
249,498 Added 1511.1%
266,009 $1.95 Million
Q4 2023

Feb 09, 2024
SELL
$1.65 - $3.94 $57 - $137
-35 Reduced 0.21%
16,511 $61,000
Q3 2023

Nov 13, 2023
SELL
$2.02 - $5.04 $21,311 - $53,172
-10,550 Reduced 38.94%
16,546 $35,000
Q2 2023

Aug 11, 2023
BUY
$4.76 - $6.59 $128,976 - $178,562
27,096 New
27,096 $128,000
Q3 2022

Nov 14, 2022
SELL
$21.04 - $36.06 $3.67 Million - $6.28 Million
-174,255 Reduced 26.29%
488,558 $10.9 Million
Q2 2022

Aug 11, 2022
SELL
$17.78 - $42.39 $21,087 - $50,274
-1,186 Reduced 0.18%
662,813 $16.4 Million
Q1 2022

May 13, 2022
SELL
$29.67 - $60.28 $574,796 - $1.17 Million
-19,373 Reduced 2.83%
663,999 $25.7 Million
Q4 2021

Feb 11, 2022
SELL
$47.84 - $64.34 $259,866 - $349,494
-5,432 Reduced 0.79%
683,372 $40 Million
Q3 2021

Nov 12, 2021
SELL
$59.27 - $95.73 $446,421 - $721,038
-7,532 Reduced 1.08%
688,804 $40.8 Million
Q2 2021

Aug 13, 2021
SELL
$67.25 - $92.52 $4.12 Million - $5.66 Million
-61,196 Reduced 8.08%
696,336 $60.4 Million
Q1 2021

May 13, 2021
BUY
$72.16 - $117.4 $186,894 - $304,066
2,590 Added 0.34%
757,532 $62.5 Million
Q4 2020

Feb 10, 2021
SELL
$38.09 - $100.95 $13.8 Million - $36.6 Million
-362,200 Reduced 32.42%
754,942 $68.6 Million
Q3 2020

Nov 12, 2020
SELL
$30.41 - $40.5 $995,076 - $1.33 Million
-32,722 Reduced 2.85%
1,117,142 $44.7 Million
Q2 2020

Aug 13, 2020
SELL
$20.21 - $35.23 $7,578 - $13,211
-375 Reduced 0.03%
1,149,864 $38.6 Million
Q1 2020

May 13, 2020
SELL
$17.28 - $31.88 $10.6 Million - $19.6 Million
-613,582 Reduced 34.79%
1,150,239 $25.5 Million
Q4 2019

Feb 12, 2020
SELL
$13.39 - $20.73 $7.43 Million - $11.5 Million
-554,900 Reduced 23.93%
1,763,821 $34.5 Million
Q3 2019

Nov 14, 2019
SELL
$15.47 - $22.5 $9.62 Million - $14 Million
-621,800 Reduced 21.15%
2,318,721 $36 Million
Q2 2019

Aug 14, 2019
SELL
$15.61 - $20.44 $4.1 Million - $5.37 Million
-262,500 Reduced 8.2%
2,940,521 $59.7 Million
Q1 2019

May 14, 2019
SELL
$13.15 - $18.71 $548,157 - $779,926
-41,685 Reduced 1.28%
3,203,021 $56.3 Million
Q4 2018

Feb 12, 2019
SELL
$11.48 - $16.98 $24.3 Million - $35.9 Million
-2,113,559 Reduced 39.44%
3,244,706 $41.6 Million
Q3 2018

Nov 13, 2018
SELL
$8.75 - $16.29 $1.51 Million - $2.81 Million
-172,484 Reduced 3.12%
5,358,265 $87.3 Million
Q2 2018

Aug 14, 2018
SELL
$9.16 - $13.48 $2.91 Million - $4.29 Million
-318,030 Reduced 5.44%
5,530,749 $62.7 Million
Q1 2018

May 10, 2018
SELL
$6.3 - $13.77 $1.18 Million - $2.57 Million
-187,000 Reduced 3.1%
5,848,779 $57.1 Million
Q4 2017

Feb 14, 2018
SELL
$3.94 - $6.64 $161,934 - $272,904
-41,100 Reduced 0.68%
6,035,779 $36.9 Million
Q3 2017

Nov 13, 2017
BUY
$2.6 - $4.31 $15.8 Million - $26.2 Million
6,076,879
6,076,879 $24.1 Million

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Franklin Resources Inc Portfolio

Follow Franklin Resources Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email